Manpreet Kaur

Manpreet Kaur

Auto-generated profile, based on publicly available information

Manpreet Kaur

David Braley Centre for Antibiotics Discovery, McMaster University, Hamilton, Ontario, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in Nature
Verified
Journal Article
Closed access
PDF file
MJManoj Jangra
Manoj Jangra
DTDmitrii Y Travin
Dmitrii Y Travin
EAElena V Aleksandrova
Elena V Aleksandrova
MKManpreet Kaur
Manpreet Kaur
LDLena Darwish
Lena Darwish
GWGerard D Wright
Gerard D Wright

1 June 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MJManoj Jangra
Manoj Jangra
MKManpreet Kaur
Manpreet Kaur
RTRushikesh Tambat
Rushikesh Tambat
RRRohit Rana
Rohit Rana
SMSushil K. Maurya
Sushil K. Maurya
DR HEMRAJ NANDANWARDR HEMRAJ NANDANWAR
DR HEMRAJ NANDANWAR
The World Health Organization has categorized the Gram-negative superbugs, which are inherently impervious to many antibiotics, as critical priority pathogens due to the lack of effective treatments. The breach in our last-resort antibiotic (i.e., colistin) by extensively drug-resistant and pan-drug-resistant Enterobacteriaceae strains demands the immediate development of new therapies.

6 September 2017 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
MKManpreet Kaur
Manpreet Kaur
HSHarjodh Singh
Harjodh Singh
MJManoj Jangra
Manoj Jangra
LKLakhwinder Kaur
Lakhwinder Kaur
PJPallavi Jaswal
Pallavi Jaswal
APAnil Kumar Pinnaka
Anil Kumar Pinnaka

23 November 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
MJManoj Jangra
Manoj Jangra
HRHarmandeep Kaur Randhawa
Harmandeep Kaur Randhawa
MKManpreet Kaur
Manpreet Kaur
ASAnugya Srivastava
Anugya Srivastava
NMNavdezda Maurya
Navdezda Maurya
DR HEMRAJ NANDANWARDR HEMRAJ NANDANWAR
DR HEMRAJ NANDANWAR
Nosocomial infections caused by antibiotic-resistant Gram-negative pathogens are of grave concern today. Polymyxins are considered as the last resorts of therapy to treat these multi-drug resistant (MDR) bacteria. But their associated nephrotoxicity and neurotoxicity calls for the development of safer polymyxin therapy until novel and less toxic antibiotics are discovered. No other polymyxin molecule except polymyxin B and E (colistin) is explored thoroughly in literature to demonstrate its clinical relevance. In the present study, we have isolated two antimicrobial compounds named P1 and P2 from the soil isolate Paenibacillus dendritiformis strain PV3-16, which we later identified as polymyxin A2 and A1 respectively. We tested their minimum inhibitory concentrations (MICs) against MDR clinical isolates, performed membrane permeabilization assays and determined their interaction with lipopolysaccharide (LPS). Finally, we studied their toxicity against human Leukemic monocyte cell line (THP-1) and embryonic kidney cell line (HEK 293). Both compounds displayed equal efficacy when compared with standard polymyxins. P1 was 2–4 fold more active in most of the clinical strains tested. Moreover, P1 showed higher affinity toward LPS. In cytotoxicity studies, P1 had IC50 value (>1000 μg/ml) similar to colistin against HEK cells but immune cells, i.e., THP-1 cell lines were more sensitive to polymyxins. P1 showed less toxicity in THP-1 cell line than all other polymyxins checked. To sum up, P1 (polymyxin A2) possessed better efficacy than polymyxin B and E and had least toxicity to immune cells. Since polymyxin A was not investigated thoroughly, we performed the comprehensive in vitro assessment of this molecule. Moreover, this is the first report of isolation and characterization of polymyxin A from P. dendritiformis. This compound should be further investigated for its in vivo efficacy and toxicity to develop it as a drug candidate.

1 June 2019 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
MJManoj Jangra
Manoj Jangra
MKManpreet Kaur
Manpreet Kaur
DR HEMRAJ NANDANWARDR HEMRAJ NANDANWAR
DR HEMRAJ NANDANWAR

1 February 2018 in International Journal of Systematic and Evolutionary Microbiology
Verified
Journal Article
Closed access
MKManpreet Kaur
Manpreet Kaur
HSHarjodh Singh
Harjodh Singh
SSShivani Sharma
Shivani Sharma
SMSunita Mishra
Sunita Mishra
NTNaga Radha Srinivas Tanuku
Naga Radha Srinivas Tanuku
APAnil Kumar Pinnaka
Anil Kumar Pinnaka
A novel Gram-negative, rod shaped, non-motile bacterium, designated strain YK2T, was isolated from yak milk from Leh, India. The strain was positive for oxidase- and catalase-activities and negative for starch hydrolysis, nitrate reduction, citrate utilization, urease, lysine decarboxylase and ornithine decarboxylase activities. The predominant fatty acids were iso-C15 : 0, iso-C17 : 0 3-OH, iso-C17 : 1ω9c and C16 : 1 ω7c and/or C16 : 1ω6c and/or iso-C15 : 0 2-OH (summed feature 3). The major polar lipids were phosphatidylethanolamine, one unidentified aminophospholipid and six unidentified lipids. The DNA G+C content of the strain was 38.9 mol%. The 16S rRNA gene sequence analysis indicated that strain YK2T was a member of the genus Sphingobacterium and closely related to Sphingobacterium alimentarium and Sphingobacterium composti with pair-wise sequence similarity of 98.3 and 97.9 %, respectively. The sequence similarity to other members of the genus Sphingobacterium was between 92.6 to 96.3 %. Phylogenetic analysis showed that strain YK2T clustered with Sphingobacterium alimentarium and together clustered with Sphingobacterium composti . DNA–DNA hybridization of strain YK2T with Sphingobacterium alimentarium WCC 4521T and Sphingobacterium composti T5-12T showed a relatedness of only 38 and 54 %, respectively. Based on the phenotypic characteristics and on phylogenetic inference, it appears that strain YK2T represents a novel species of the genus Sphingobacterium , for which the name Sphingobacterium bovisgrunnientis sp. nov. is proposed. The type strain of Sphingobacterium bovisgrunnientis sp. nov. is YK2T (=MTCC 12631T=KCTC 52685T=JCM 31951T).